Abstract
Intermediate endpoints (e.g., disease-free survival [DFS]) have shown very good correlation with overall survival (OS) in early-stage non-small cell lung cancer (NSCLC) clinical trials. Yet limited studies quantified the clinical and economic burden of disease recurrence in this population in the real-world. This study aims to assess the association between real-world DFS (rwDFS) and OS and estimate the clinical and economic burden associated with recurrence among patients with resected early-stage NSCLC.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call